Search results
Showing 421 to 423 of 423 results for additional lines of treatment process
appraisal recommendations Compliance with nice-approved medicines or treatments Data collection agreement UK licensing and technology...
NICE announces start of review of nusinersen Managed Access Agreement
NICE has today (29 October 2020) announced that it has begun the process to review data collected as part of the Managed Access Agreement (MAA) for nusinersen.
NICE responds to failure of talks to reach price agreement on Enhertu
Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.